Skip to main content

Table 3 Detailed information of ROC curve analysis

From: Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition

Panel AUC Sensitivity (%) Specificity (%) P value Cutoff criterion 95% CI of AUC
ND– vs ND+
 MPP-Aβ42/40 0.639 71.8 51.5 <0.0001 >0.1871 0.559–0.719
 MPP-Aβ42/40 + age + gender 0.695 79.0 57.8 <0.0001 >0.1864 0.622–0.767
 MPP-Aβ42/40 + age + gender + ApoE 0.783 80.7 69.2 <0.0001 >0.1730 0.715–0.852
PiB– vs PiB+
 MPP-Aβ42/40 0.668 71.0 52.2 <0.0001 >0.2731 0.605–0.731
 MPP-Aβ42/40 + age + gender 0.682 71.0 54.2 <0.0001 >0.2759 0.622–0.741
 MPP-Aβ42/40 + age + gender + ApoE 0.799 78.0 66.8 <0.0001 >0.2230 0.746–0.852
  1. ApoE Apolipoprotein E, AUC area under curve, MPP mixture of protease inhibitors and phosphatase inhibitors, CI confidence interval, ROC receiver operating characteristic, – or + PiB-PET positivity, ND– PiB-PET-negative cognitively normal (CN) and PiB-PET-negative subjects with mild cognitive impairment (MCI), ND+ PiB-PET-positive CN and PiB-PET-positive MCI, PiB– grouped CN–, MCI–, and ADD–, PiB+ grouped CN+, MCI+, and ADD+